Drugs that contain Metformin Hydrochloride; Saxagliptin Hydrochloride
1. Kombiglyze Xr patents expiration
KOMBIGLYZE XR's oppositions filed in EPO
KOMBIGLYZE XR Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6395767 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb, 2021
(3 years ago) | |
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage
KOMBIGLYZE XR family patents
